KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Research & Development (2016 - 2025)

NovoCure (NVCR) has disclosed Research & Development for 12 consecutive years, with $60.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 18.93% to $60.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $224.5 million through Dec 2025, up 7.11% year-over-year, with the annual reading at $224.5 million for FY2025, 7.11% up from the prior year.
  • Research & Development hit $60.9 million in Q4 2025 for NovoCure, up from $54.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $60.9 million in Q4 2025 to a low of $42.2 million in Q1 2022.
  • Historically, Research & Development has averaged $53.2 million across 5 years, with a median of $53.9 million in 2025.
  • Biggest five-year swings in Research & Development: skyrocketed 81.69% in 2021 and later fell 13.58% in 2024.
  • Year by year, Research & Development stood at $56.9 million in 2021, then fell by 3.71% to $54.8 million in 2022, then fell by 0.93% to $54.3 million in 2023, then fell by 5.7% to $51.2 million in 2024, then grew by 18.93% to $60.9 million in 2025.
  • Business Quant data shows Research & Development for NVCR at $60.9 million in Q4 2025, $54.0 million in Q3 2025, and $55.8 million in Q2 2025.